ArticleGut microbes
A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2.
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Towards optimizing the host response to biotics: a report of an International Scientific Association for Probiotics and Prebiotics working group.Gut microbes · 2026Article
- Navigating multi-omic integration methods for human microbiome research.Nature microbiology · 2026Review
- Prognostic prediction in COVID-19 patients: a comprehensive analysis of gut microbiota and hematological biomarkers.Virus research · 2026Article
- Integrative metagenomics and metabolomics reveal age-associated gut microbiota and metabolite alterations in a hamster model of COVID-19.Gut microbes · 2025Article
- B. adolescentis alleviates inflammation and suppresses PGE2 through remodling gut microbiota to attenuate pulmonary fibrosis in aging mice.NPJ science of food · 2025Article
- Changes in Probiotic Lachnospiraceae Genera Across Different Stages of COVID-19: A Meta-Analysis of 16S rRNA Microbial Data.Microorganisms · 2025Article
- The Role of Beneficial Microbiota in COVID-19: Insights from Key Bacterial Genera.Microorganisms · 2025Review
- Article
- Review
- In Silico Analysis of Probiotic Bacteria Changes Across COVID-19 Severity Stages.Microorganisms · 2024Article
- Exploring Prior Antibiotic Exposure Characteristics for COVID-19 Hospital Admission Patients: OpenSAFELY.Antibiotics (Basel, Switzerland) · 2024Article
- Bile acids and coronavirus disease 2019.Acta pharmaceutica Sinica. B · 2024Review
- Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.International journal of molecular sciences · 2024Review
- Clinical courses and outcomes of COVID-19 associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 omicron variant.BMC infectious diseases · 2024Article
- Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19.Microbiology spectrum · 2024Article
- The association of three vaccination doses with reduced gastrointestinal symptoms after severe acute respiratory syndrome coronavirus 2 infections in patients with inflammatory bowel disease.Frontiers in medicine · 2024Article
- The Role of Bifidobacterium in COVID-19: A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Gut microbiome immaturity and childhood acute lymphoblastic leukaemia.Nature reviews. Cancer · 2023Review
- Repeated antibiotic exposure and risk of hospitalisation and death following COVID-19 infection (OpenSAFELY): a matched case-control study.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and associated clinical sequelae requires well-coordinated metabolic and immune responses that limit viral spread and promote recovery of damaged systems. However, the role of the gut microbiota in regulating these responses has not been thoroughly investigated. In order to identify mechanisms underpinning microbiota interactions with host immune and metabolic systems that influence coronavirus disease 2019 (COVID-19) outcomes, we performed a multi-omics analysis on hospitalized COVID-19 patients and compared those with the most severe outcome (i.e. death, n = 41) to those with severe non-fatal disease (n = 89), or mild/moderate disease (n = 42), that recovered. A distinct subset of 8 cytokines (e.g. TSLP) and 140 metabolites (e.g. quinolinate) in sera identified those with a fatal outcome to infection. In addition, elevated levels of multiple pathobionts and lower levels of protective or anti-inflammatory microbes were observed in the fecal microbiome of those with the poorest clinical outcomes. Weighted gene correlation network analysis (WGCNA) identified modules that associated severity-associated cytokines with tryptophan metabolism, coagulation-linked fibrinopeptides, and bile acids with multiple pathobionts, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.